Upgrade to SI Premium - Free Trial

Sanofi (SNY) Reports Isatuximab Phase 3 Trial Meets Primary Endpoint of Prolonging Progression Free Survival in Patients with Relapsed/Refractory Multiple Myeloma

February 5, 2019 5:45 AM
Sanofi (NYSE: SNY) announces that the pivotal Phase 3 trial of isatuximab in patients with relapsed/refractory multiple myeloma met the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA Hot Corp. News Hot FDA News Management Comments

Next Articles